ERA-NET-Cofund TRANSCAN-3 Joint Transnational Call (2022) “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”

The goal of  TRANSCAN-3  is coordinating national and regional funding programmes for research in the area of translational cancer research. Twenty four funding organisations from seventeen countries have agreed to launch a Joint Transnational Call (JTC 2022), for collaborative research projects on "Novel translational approaches to tackle the challenges of Hard-To-Treat Cancers from early diagnosis to therapy". The participating TRANSCAN-3 funding organisations wish to promote innovative interdisciplinary collaboration and truly translational research projects aiming at promoting highly innovative and ambitious collaborative projects in translational cancer research at European and International level. 

Additional Information

In the context of translational research, this topic at the intersection of laboratory and clinical research in immuno-oncology will comprise three general aims listed below which correspond to the possible clinical applications. 

Approaches should be directed towards identification or validation of novel early diagnostic and/or therapeutic approaches for Hard-To-Treat Cancers  HTTCs. Projects should be built from a solid and established hypothesis and should be relevant with regards to the possible improvements in clinical practice.

Aim 1: Identification/validation of novel early diagnostic approaches. (NB: Irish partners are not eligible for HRB funding for Aim 1.2, involving non-confirmatory clinical trials.)

Aim 2: Identification/validation of novel therapeutic approaches. (NB: Irish partners are not eligible for HRB funding for Aim 2.2, involving phase I and II clinical trials.)

Aim 3: Development of novel drug delivery strategies.

The following types of research projects are excluded from the call:


This is a joint transnational call: applicants must apply as part of a transnational consortium.

Researchers from Ireland can apply as coordinators or partners. If successful, researchers from Ireland will be funded by the Health Research Board up to the maximum amount for the call. Applicants applying for funding from Ireland must be based at an eligible HRB Host Institution.

Individual country partners/coordinators should confirm eligibility with their national funding organisation contact point. 

Main Eligibility Criteria

  • Only transnational projects will be funded.
  • Each consortium must involve funded partners from at least three different countries participating in this call.
  • Each proposal must involve a minimum of three and a maximum of six partners (principal investigators) eligible for funding.
  • In addition a consortium can have a maximum of two partners from the same country. In such cases the minimum number of research groups must be four, coming from three different countries.
  • A maximum of one partner bringing its own funding (i.e., ineligible for funding from one of the funding organisations) is allowed in consortia where at least three partners are eligible. 
  • In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Latvia, Slovakia and Turkey.
  • Each consortium must involve at least one basic or pre-clinical research team and one clinical team. It is also recommended to include an expert team in methodology, biostatistics or bioinformatics, depending on the type of work planned.

Please review the published text for full details of the aim, objectives and scope of the call:


Both pre and full proposals must be written in English and must be submitted to the Joint Call Secretariat by the coordinator through the PT-Outline electronic submission system exclusively. 

(See for further details)


General Queries: Joint Call Secretariat (JCS 2022) at:
Ministero della Salute - Istituto Superiore di Sanità, Italy
Silvia Paradisi
 e-mail: jtc2022(at)

Applicants from Ireland should read the information in the HRB Guidance notes and HRB FAQ on this webpage. If you have further questions, you can contact Dr Siobhán Hackett at HRB email

Opening date
15:00 06-06-2022
Closing date
11:00 18-07-2022
Decision expected
17 November 2022